The impact of macrophage-cancer cell interaction on the efficacy of photodynamic therapy

Macrophages are one of the principal host cell populations in solid tumors. They are capable, due to their plasticity, of acquiring phenotypes that either combat (M1 type) or promote (M2 type) neoplastic growth. These cells, known as tumor-associated macrophages (TAMs), play complex but pivotal roles in the outcome of photodynamic therapy (PDT) of malignant lesions. Among the various parenchymal and stromal cell populations found in tumors, TAMs have been shown to have the greatest capacity for the uptake of systemically administered photosensitizers. Both the tumor-localizing property of photosensitizers and their tumor-localized fluorescence could be partly attributed to the activity of TAMs. Since resident TAMs with accumulated high photosensitizer content will sustain high degrees of PDT damage, this population (predominantly M2 in most tumors) is selectively destroyed, and during the ensuing inflammatory reaction is replaced with newly invading macrophages of M1 phenotype. These macrophages are sentinels responding to DAMP signals from PDT-treated tumor cells and in turn are mobilized to generate a variety of inflammatory/immune mediators and opsonins. They have a critical role in contributing to the therapeutic effect of PDT by mediating disposal of killed cancer cells and by processing/presenting tumor antigens to T lymphocytes. However, TAMs accumulating in the later post-PDT phase can acquire the M2 (healing) phenotype, and could have a role in tumor recurrence by releasing factors that promote angiogenesis and the survival/proliferation of remaining cancer cells. Various therapeutic strategies modulating TAM activity in the PDT response have potential for clinical use for improving PDT-mediated tumor control.

[1]  Mladen Korbelik,et al.  Complement activation approaches for use in conjunction with PDT for cancer treatment , 2005, SPIE BiOS.

[2]  T. Dougherty,et al.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. , 1981, Cancer research.

[3]  Michael R Hamblin,et al.  Macrophage-Targeted Photodynamic Therapy: Scavenger Receptor Expression and Activation State , 2005, International journal of immunopathology and pharmacology.

[4]  Klaus Ley,et al.  M1 and M2 Macrophages: The Chicken and the Egg of Immunity , 2014, Journal of Innate Immunity.

[5]  C. Gomer,et al.  Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment , 2006, Lasers in surgery and medicine.

[6]  B. Lau,et al.  Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. , 1989, Urology.

[7]  M. Korbelik,et al.  Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. , 1998, Journal of photochemistry and photobiology. B, Biology.

[8]  Mladen Korbelik,et al.  ENHANCED MACROPHAGE CYTOTOXICITY AGAINST TUMOR CELLS TREATED WITH PHOTODYNAMIC THERAPY , 1994, Photochemistry and photobiology.

[9]  F. Sutterwala,et al.  Sterile inflammatory responses mediated by the NLRP3 inflammasome , 2010, European journal of immunology.

[10]  M. Korbelik,et al.  Exploitation of Immune Response‐eliciting Properties of Hypocrellin Photosensitizer SL052‐based Photodynamic Therapy for Eradication of Malignant Tumors , 2009, Photochemistry and photobiology.

[11]  D. Xing,et al.  Regulation of HSP70 on activating macrophages using PDT‐induced apoptotic cells , 2009, International journal of cancer.

[12]  J. Marshall,et al.  Tissue uptake, distribution, and potency of the photoactivatable dye chloroaluminum sulfonated phthalocyanine in mice bearing transplantable tumors. , 1988, Cancer research.

[13]  M. Korbelik,et al.  Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. , 2008, Journal of photochemistry and photobiology. B, Biology.

[14]  M. Korbelik,et al.  Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. , 1997, British Journal of Cancer.

[15]  B W Henderson,et al.  Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction. , 1989, Ciba Foundation symposium.

[16]  Michael R Hamblin,et al.  Scavenger-Receptor Targeted Photodynamic Therapy¶ , 2000, Photochemistry and photobiology.

[17]  Gorazd Krosl,et al.  Can PDT be potentiated by immunotherapy? , 1993, Other Conferences.

[18]  P. Allavena,et al.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions , 2013, Seminars in Immunopathology.

[19]  M. Korbelik,et al.  Accumulation of benzoporphyrin derivative in malignant and host cell populations of the murine RIF tumor. , 1995, Cancer letters.

[20]  J. Krosl,et al.  Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. , 1996, Cancer research.

[21]  C. Gomer,et al.  Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. , 2007, Cancer research.

[22]  Michael R Hamblin,et al.  On the mechanism of the tumour-localising effect in photodynamic therapy. , 1994, Journal of photochemistry and photobiology. B, Biology.

[23]  S. Grinstein,et al.  Scavenger receptors in homeostasis and immunity , 2013, Nature Reviews Immunology.

[24]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[25]  C. Gomer,et al.  Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. , 2006, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[26]  Mladen Korbelik,et al.  Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors , 2004, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[27]  M. Korbelik,et al.  Role of Complement Anaphylatoxin C3a in Photodynamic Therapy-elicited Engagement of Host Neutrophils and Other Immune Cells , 2006, Photochemistry and photobiology.

[28]  M. Korbelik,et al.  Photofrin accumulation in malignant and host cell populations of various tumours. , 1996, British Journal of Cancer.

[29]  M. Korbelik,et al.  Distribution of Photofrin between tumour cells and tumour associated macrophages. , 1991, British Journal of Cancer.

[30]  M. Korbelik,et al.  THE EFFECT OF DIFFERENTIATION ON PHOTOSENSITIZER UPTAKE BY HL60 CELLS , 1993, Photochemistry and photobiology.

[31]  M. Korbelik,et al.  Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy , 2007, Cancer Immunology, Immunotherapy.

[32]  J. M. Marchetti,et al.  Photobiological and Ultrastructural Studies of Nanoparticles of Poly(lactic-co-glycolic acid)-Containing Bacteriochlorophyll-a as a Photosensitizer Useful for PDT Treatment , 2005, Drug delivery.

[33]  J. Marshall,et al.  EFFECT OF PHOTODYNAMIC THERAPY ON ANTITUMOR IMMUNE DEFENSES: COMPARISON OF THE PHOTOSENSITIZERS HEMATOPORPHYRIN DERIVATIVE AND CHLORO‐ALUMINUM SULFONATED PHTHALOCYANINE , 1989, Photochemistry and photobiology.

[34]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[35]  J. Norton,et al.  Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. , 1990, Journal of the National Cancer Institute.

[36]  Youngmi Kim,et al.  ROS-Responsive Activatable Photosensitizing Agent for Imaging and Photodynamic Therapy of Activated Macrophages , 2013, Theranostics.

[37]  K. Sano,et al.  Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma , 2000, Cancer Immunology, Immunotherapy.

[38]  M. Korbelik,et al.  Distribution of disulfonated and tetrasulfonated aluminum phthalocyanine between malignant and host cell populations of a murine fibrosarcoma. , 1993, Journal of Photochemistry and Photobiology. B: Biology.

[39]  M. Gwinn,et al.  Respiratory Burst: Role in Signal Transduction in Alveolar Macrophages , 2006, Journal of toxicology and environmental health. Part B, Critical reviews.

[40]  Mladen Korbelik,et al.  PDT‐associated host response and its role in the therapy outcome , 2006, Lasers in surgery and medicine.

[41]  Wei Zhang,et al.  Ceramide and Sphingosine-1-Phosphate/Sphingosine act as Photodynamic Therapy-Elicited Damage-Associated Molecular Patterns: Release from Cells and Impact on Tumor-Associated Macrophages , 2014 .

[42]  Michael R Hamblin,et al.  Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. , 2006, Molecular pharmaceutics.

[43]  Michael R Hamblin,et al.  Photosensitizer delivery to vulnerable atherosclerotic plaque: comparison of macrophage-targeted conjugate versus free chlorin(e6). , 2006, Journal of biomedical optics.

[44]  M. Korbelik Complement upregulation in photodynamic therapy-treated tumors: Role of Toll-like receptor pathway and NFkappaB. , 2009, Cancer letters.

[45]  G. Jori,et al.  In vivo transport and pharmacokinetic behavior of tumour photosensitizers. , 1989, Ciba Foundation symposium.

[46]  M. Korbelik,et al.  Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer. , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[47]  M. Korbelik,et al.  Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. , 1994, British Journal of Cancer.

[48]  Michael R Hamblin,et al.  Macrophage-Targeted Photodynamic Therapy , 2004, International journal of immunopathology and pharmacology.

[49]  M. Korbelik,et al.  Interaction Between Photodynamic Therapy and BCG Immunotherapy Responsible for the Reduced Recurrence of Treated Mouse Tumors¶ , 2001 .

[50]  Barbara Owczarczak,et al.  Photodynamic therapy and anti‐tumor immunity , 2006, Lasers in surgery and medicine.

[51]  M. Korbelik,et al.  Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). , 1994, Cancer letters.

[52]  Mladen Korbelik,et al.  Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. , 2005, Cancer research.

[53]  Cees van Kooten,et al.  Recognition and clearance of apoptotic cells: a role for complement and pentraxins. , 2003, Trends in immunology.

[54]  M. Korbelik,et al.  Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin , 2006, British Journal of Cancer.

[55]  N. Yamamoto,et al.  TUMORICIDAL CAPACITIES OF MACROPHAGES PHOTODYNAMICALLY ACTIVATED WITH HEMATOPORPHYRIN DERIVATIVE , 1992, Photochemistry and photobiology.

[56]  M W Berns,et al.  Activation of macrophages by Photofrin II during photodynamic therapy. , 1991, Journal of photochemistry and photobiology. B, Biology.

[57]  M. Korbelik,et al.  Photofrin uptake by murine macrophages. , 1991, Cancer research.

[58]  B. Ortel,et al.  Degree of substitution of chlorin e6 on charged poly-L-lysine chains affects their cellular uptake, localization and phototoxicity towards macrophages and cancer cells. , 2002, Journal of X-ray science and technology.

[59]  Michael R Hamblin,et al.  Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor , 2008, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[60]  D. Xing,et al.  PDT‐induced HSP70 externalization up‐regulates NO production via TLR2 signal pathway in macrophages , 2013, FEBS letters.

[61]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[62]  M. Epple,et al.  Positively charged calcium phosphate/polymer nanoparticles for photodynamic therapy , 2010, Journal of materials science. Materials in medicine.

[63]  M. Korbelik Tumor-Localized Insult Delivered by Photodynamic Therapy and the Breakdown of Tumor Immunotolerance , 2013 .

[64]  P. Mróz,et al.  Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  M. Korbelik,et al.  Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. , 1995, British Journal of Cancer.

[66]  Michael R Hamblin,et al.  Photodynamic therapy and anti-tumour immunity , 2006, Nature Reviews Cancer.

[67]  H. Herwald,et al.  The Janus Face of Macrophages in Immunity , 2014, Journal of Innate Immunity.